Immutep's Upcoming Presentation at ESMO 2024
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a pioneering biotechnology company, is gearing up to present compelling new results from its research at the prestigious European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024, scheduled for December 11-13 in Geneva. The data to be shared focuses on patients with first line recurrent or metastatic head and neck squamous cell carcinoma exhibiting negative PD-L1 expression (CPS <1), a critical area of study in cancer treatment.
Details of the Presentation
With a focus on the TACTI-003 Phase IIb trial, Immutep will present findings from Cohort B, which explores the combination of Eftilagimod Alpha (an innovative LAG-3 immunotherapy) alongside Pembrolizumab. Leading the presentation will be Dr. Martin Forster from University College London, a respected authority in cancer research.
Presentation Highlights
- Title: TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma with CPS <1
- Presenter: Dr. Martin Forster, M.D., Ph.D.
- Presentation Number: 152P
- Date and Time: December 12, 12:30 – 13:30 PM CET
What to Expect
On December 5, the abstracts detailing the findings will be accessible on the ESMO I-O website, showcasing Immutep's commitment to advancing cancer treatments. Moreover, attendees can look forward to a dedicated poster that will include additional data not found in the abstract, ensuring a comprehensive understanding of the research being presented.
About Immutep and Its Innovative Research
Immutep is known for its cutting-edge LAG-3 immunotherapy developments targeting both cancer and autoimmune conditions. As innovators in immunotherapy, the company is dedicated to exploring the full potential of Lymphocyte Activation Gene-3 (LAG-3) to create therapies that can either stimulate or modulate the immune response. This commitment plays a crucial role in the goal of providing patients with effective treatment alternatives while maximizing shareholder value.
Immutep’s Vision
The company's research into LAG-3 translates into the creation of advanced therapeutic options. By harnessing its understanding of the immune system, Immutep strives to be at the forefront of treatment innovation and patient care, making significant strides in previously hard-to-treat cancers.
Contact for Inquiries
For any inquiries related to this presentation or further details about Immutep’s work, media representatives can reach out:
Australian Media Contact
Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media Contact
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
Frequently Asked Questions
What is the purpose of the upcoming presentation by Immutep?
The presentation aims to reveal novel data from their Phase IIb trial focusing on head and neck cancer treatment.
Who is presenting the data at ESMO 2024?
Dr. Martin Forster from University College London will lead the presentation.
When will the abstracts for the presentation be available?
The abstracts will be available on December 5 on the ESMO I-O website.
What is Eftilagimod Alpha?
Eftilagimod Alpha is a novel immunotherapy that targets the LAG-3 immune checkpoint, enhancing the body’s ability to fight cancer.
How can I contact Immutep for more information?
You can reach out to the media contacts provided for both Australian and U.S. representatives for inquiries.
